Legislation requesting more research on Alzheimer's disease in New Mexico passes
New Mexico will be the state with the fourth highest proportion of seniors in its population by 2030, according to an estimation by the Aging and Long-Term Services Department.
And of the state's current population, the New Mexico Chapter of the Alzheimer's Association reports more than 46,000 people live with a dementia-related illness.
In response to these statistics and in an effort to expand awareness of dementia-related illnesses, Rep. Pamelya Herndon (D-Albuquerque) sponsored House Memorial 53, which unanimously passed the House on Wednesday.
HM53 asks the Department of Health and the Aging and Long-Term Services Department to encourage further research on the subject and to work together to distribute updated information to New Mexicans and health providers. It also requests the departments create a report on these actions for the Legislative Council Service and the governor.
The Aging and Long-Term Services Department recently launched its 'Take Action. Talk' campaign to increase awareness of warning signs of Alzheimer's disease, treatments and resources for caregivers. The department also operates the New MexiCare program, which provides financial assistance to people who narrowly miss the requirements for qualifying for Medicaid.
Emily Kaltenbach, secretary of the Aging and Long-Term Services Department, told Source NM in an emailed statement that her department is committed to supporting people living with a dementia-related illness and caregivers.
'ALTSD is actively addressing this critical issue through initiatives like the federal Lifespan Respite grant, which provides outreach, education, and respite for caregivers,' she said.
Herndon also noted that the memorial encourages further research at the New Mexico Alzheimer's Disease Research Center at the University of New Mexico's Health Sciences Center, including clinical trials and PET scans for amyloid plaques in the brain, which have been shown to develop in the brains of people with Alzheimer's disease, according to the National Institute on Aging.
'The University of New Mexico is one of the few places that [these scans] can actually be done in this state,' Herndon said.
She told Source that she will look into how Medicaid might take part in expanding access to Alzheimer's disease drugs next session, after the departments complete their report.
Herndon told Source NM she had limited knowledge of Alzheimer's disease until a close friend received a diagnosis. And neither she nor her friend were aware of the two drugs approved in recent years by the U.S. Food and Drug Administration shown to delay cognitive decline in patients with cases of early or mild dementia caused by Alzheimer's disease.
'How would her life have changed if she had known about it,' Herndon said. 'How do we get more information out to the community about the disease, about how you can protect yourselves and your family and what you need to do to make sure you're living a long and happy life as you can. And New Mexico can take a giant place in this.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
32 minutes ago
- Axios
Medicaid effort to target undocumented immigrants may create enrollment hurdles
Federal health officials announced a new push on Tuesday to ensure that Medicaid and Children's Health Insurance Program (CHIP) enrollees are U.S. citizens or have a satisfactory immigration status. Why it matters: The effort could create new administrative hoops for enrollees to jump through. Driving the news: The Centers for Medicare and Medicaid Services will begin providing states with "monthly enrollment reports identifying individuals whose citizenship or immigration status could not be confirmed through federal databases," the Department of Health and Human Services said in a statement. The reports will draw on data from sources including the Department of Homeland Security's Systematic Alien Verification for Entitlements (SAVE) program. HHS emphasized that states are responsible for reviewing cases, verifying the immigration status of individuals on the CMS' reports, and "taking appropriate actions." All states will receive these reports within the next month, per the HHS. Reality check: Traditional Medicaid coverage is not available to undocumented immigrants. "Undocumented immigrants are not eligible to enroll in federally funded coverage including Medicaid, CHIP, or Medicare or to purchase coverage through the ACA Marketplaces," per the non-partisan Kaiser Family Foundation. HHS did not respond to Axios' request for comment. What they're saying:"Every dollar misspent is a dollar taken away from an eligible, vulnerable individual in need of Medicaid and CHIP," said CMS Administrator Dr. Mehmet Oz. Between the lines: The change looks to put the burden of proof on the individuals whose immigration statuses the CMS cannot verify through the databases. By the numbers: Despite the assertions of Oz — and other parts of President Trump's administration — there is not evidence that undocumented immigrants are broadly receiving Medicaid benefits they're not eligible for. Medicaid reimburses hospitals for emergency care provided to individuals who meet other eligibility requirements but lack eligible immigration status. Emergency spending rose less than 1% of total Medicaid spending between 2017 and 2023, according to KFF. Immigrants in the country legally may also qualify for Medicaid or CHIP, but face eligibility restrictions. There is a five-year waiting period for these modified forms of Medicaid and CHIP, which states can eliminate for children and pregnant people. An early version of Republicans recently passed tax-and-spending bill would have cut federal payments to states that covered undocumented immigrants with their own funds. The provision was dropped after it was found to violate Senate rules. The White House claimed that the provision would "protect Medicaid for Americans by removing at least 1.4 million illegal immigrants from the program." The other side: The 1.4 million figure "is unequivocally false," according to Georgetown University's Center for Families and Children.
Atlantic
an hour ago
- Atlantic
The Future of Alzheimer's Diagnosis Is Now
A patient enters her general practitioner's office for a routine checkup. She is 65 years old, and—knock on wood—in good health: walking outside every morning, eating a thoughtful diet, and reading voraciously. All of this she naturally tells her doctor during the visit. However, lately she's been forgetting things here and there. Nothing major, she thinks. It's just a normal part of getting older. So this small detail she keeps to herself. But by holding on to that detail, the patient is also putting off a conversation that could change the course of her life as well as her family's. Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer's disease in the United States—a number that is expected to almost double in the next few decades. The fear that talking about it will lead to a road of invasive procedures, life-changing diagnoses, and painful choices is all too common. However, new scientific developments in diagnostics have been made so medical experts can help diagnose or rule out Alzheimer's disease sooner, and more easily, than ever before with a simple blood test. In this new era, patients can rule out the disease as a diagnosis or talk to their doctors about care options and plan with their families if they receive a diagnosis. When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future Brandy Matthews Vice President of Global and U.S. Medical Affairs for Eli Lilly and Company 'We have to overcome this barrier of stigma,' says Brandy Matthews, M.D., FAAN, vice president of global and U.S. medical affairs for Alzheimer's disease at Eli Lilly and Company, 'and then the reinforcement of the myths [so] that people will raise their hand when they begin to experience changes in their memory and thinking.' In addition to the laboratory developed tests that are already available and developed under the Clinical Laboratory Improvement Amendments (CLIA) to aid in Alzheimer's disease diagnosis, the FDA recently cleared the first in vitro diagnostic (IVD) blood biomarker test. These tests can be administered to symptomatic patients as part of a cognitive workup. 'The fact that there's been a recent FDA clearance for a blood biomarker in Alzheimer's disease is really critical and really big and I think will be a sort of a monumental shift in how we diagnose Alzheimer's disease,' says Anthony 'Nino' Sireci, M.D., MSc, senior vice president of clinical biomarkers, laboratories and diagnostics at Eli Lilly and Company. The work of developing new technology to diagnose a disease is painstaking and slow, but these breakthroughs are essential for patients. These advances not only offer hope to millions but also provide researchers like Matthews and Sireci with a profound sense of purpose. 'When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future, to engage in lifestyle modifications, and to explore options for therapies that may target their symptoms or the underlying pathology of the disease,' says Matthews. Way back in 1906, the German neuropathologist Alois Alzheimer identified what he called 'an unusual disease of the cerebral cortex' marked by symptoms of memory loss. Using newly available technology, he identified two key pathological proteins in the neurons of his patients' brain cells: Beta-amyloid and tau. Beta-amyloid and tau are proteins produced naturally in the body. In patients with Alzheimer's disease, beta-amyloid starts to clump together, creating plaques between brain cells, while tau twists together into tangles inside brain cells. 'They are involved in a cascade of changes that happen in the brain, presumably initially with amyloid plaque accumulation, followed by tau tangle accumulation, leading to the dysfunction of the brain cells and then eventually neurodegeneration or shrinking of the brain. That results in the symptoms of Alzheimer's disease,' says Matthews. To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly Beta-amyloid plaques and tau tangles are the cause of the disease, but for nearly a century following their initial discovery, they could be identified only posthumously. This changed in 2002, when scientists identified amyloid plaque in the brain of a patient with a PET scan for the first time, using an imaging agent approved by the FDA in 2012. In 2022, the FDA cleared its first biomarker test measuring the presence of beta-amyloid in cerebrospinal fluid (CSF), drawn during a lumbar puncture (also known as a spinal tap). 'Modified fragments of those proteins are released into the cerebrospinal fluid,' says Sireci. 'And so those become some of the biomarkers that you measure in CSF.' While effective tools and necessary parts of the diagnostic process, PET scans and spinal taps are invasive and not always readily available, depending on where patients are located. This is where blood biomarkers come in, because beta-amyloid and tau aren't released only into CSF. 'Some of them actually leak out into the blood in super small quantities,' says Sireci. 'And that's what we use as the basis for identification of blood biomarkers in patients with Alzheimer's disease.' The traces found in these tests are smaller and harder to identify than the ones found in CSF. One challenge has been innovating over years to make blood test more closely resemble CSF – a major breakthrough developed over years of challenging work. And such tests require patients access and provider experience. In an ideal world, a simple blood sample could be collected at any doctor's office, even in rural or underserved communities, and sent to a major reference lab where, combined with the patient's initial cognitive assessment, it could provide information to help the treating physician to diagnose Alzheimer's disease without the need for additional confirmatory testing. That would vastly expand access to timely diagnosis. But there is still a lot of work to do between the clearance of a medical technology and its implementation. 'The obstacles now are not scientific,' says Sireci. 'Medicine is a logistical effort.' Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big. Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly 'It's implementation,' he says. 'Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big.' But with any new diagnostic tools come questions. Are physicians educated in how to understand the results? Are they confident in those results? And once they are, are they actually able to order the test at scale from high quality labs? It's about quality and it's about access. And that's only on the medical side. What about patients? Will insurers reimburse the tests so that patients are not faced with high out-of-pocket costs? Will patients embrace them? Sireci is optimistic about both possibilities. A recent survey by the Alzheimer's Association found that 91 percent of patients would want a blood biomarker test if it were made available to them. A readily available blood biomarker test gives doctors and patients a tool to aid in accurate and timely diagnosis. That patient who walked into her general practitioner's office? She would undergo a routine cognitive exam (a recommended standard for all patients 65 and older). She would have an honest conversation with her doctor about changes she might be perceiving in her brain function, however slight. And if the doctor thought it was necessary, a referral to a specialist for a simple blood test would be administered to help inform next steps. Then, unlike in the decades when Alzheimer's disease could be diagnosed only symptomatically or after an invasive procedure, the doctor would lead her in an informed, fact-based discussion—right away. From that conversation, the patient could undergo a PET scan or CSF testing to confirm or rule out the diagnosis if necessary. 'To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged,' says Sireci, 'but also [that] they're not waiting years for a diagnosis, which unfortunately is what's happening today.' We're moving the needle for patients and giving physicians another very powerful tool to combat this disease. Anthony 'Nino' Sireci M.D., Senior Vice President of Diagnostics Development at Lilly This is crucial because Alzheimer's is a progressive disease. Timing is critical. The earlier a patient is diagnosed, the more time they have for planning, which could include treatment options a patient has available to them. They can set themselves up for counseling, talk to their families, and could choose to begin medical intervention. 'We've learned over time that initiating therapy in the earlier stages of disease can have greater impact,' says Matthews. 'And even within those early symptomatic stages of disease, there's evidence, across a class of medicines, that the earliest stages of early symptomatic Alzheimer's disease may demonstrate the greatest benefit of new therapies.' For Sireci, who has experience with Alzheimer's disease both as a doctor and as the family member of a patient, the most gratifying aspect of his research is knowing that it can help shorten what he calls the 'diagnostic odyssey.' 'Even if that just means getting the conversation to happen for the physician faster than it would've, then I'm happy,' says Sireci. 'That's a really big deal. We're moving the needle for patients and giving physicians another very powerful tool to combat this disease.' The Future of Alzheimer's Diagnosis Is Now Hear more from Brandy Matthews, Vice President of Global and U.S. Medical Affairs at Eli Lilly and Company, on the future of Alzheimer's diagnosis. learn more
Yahoo
3 hours ago
- Yahoo
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
Elevance Health, Inc. ELV is taking a bold step in the delivery of primary care by integrating Food as Medicine into its care model. By partnering with the National Association of Community Health Centers (NACHC), the company aims to integrate nutrition into treatment plans, along with prescriptions and diagnostics. This program expands ELV's existing regional Nourished Well initiative. Elevance Health Foundation will also support NACHC with a six-month Food as Medicine grant. Through this collaboration, primary care teams at Community Health Centers (CHCs) will be trained to effectively screen and connect Medicaid patients with personalized nutrition support. This includes medically tailored meals, coaching and lifestyle interventions. As CHC is serving around 34 million Americans, this program aims to reduce food and nutrition insecurities while enhancing chronic disease management and preventive health outcomes. By incorporating these services within the care processes, ELV and NACHC are breaking down barriers to access and establishing a sustainable model for achieving long-term health outcomes. Looking ahead, ELV, NACHC and CHCs aim to serve as a scalable national model that promotes food-based clinical care by developing a Nutrition Center of Excellence. If a nutrition-focused strategy turns out to be effective, it might open the door to wider acceptance across the U.S. healthcare system. ELV's individual medical membership rose 5.2% year over year in the second quarter of 2025 to 1.3 million. We expect the metric to rise 0.7% year over year in 2025. How Are Competitors Faring? Some of ELV's competitors in the medical space are Centene Corporation CNC and The Cigna Group CI. Centene's high-acuity Medicaid membership grew 6.2% year over year in the second quarter of 2025. Its total membership was around 28 million as of June 30, 2025. Centene's total revenues rose 22.4% year over year in second-quarter 2025. Cigna reported 3.2% year-over-year growth in international health customers in the second quarter of 2025. Its total medical customers were around 18 million as of June 30, 2025. Cigna's total revenues rose 11% year over year in the second quarter of 2025. Elevance Health's Price Performance, Valuation & Estimates Shares of ELV have lost 16.1% in the year-to-date period compared with the industry's decline of 1%. Image Source: Zacks Investment Research From a valuation standpoint, Elevance Health trades at a forward price-to-earnings ratio of 9.62, down from the industry average of 15.08. ELV has a Value Score of A at present. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Elevance Health's 2025 earnings is pegged at $30.59 per share, implying a 7.4% decline from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
